Needham analyst David b lowered the firm’s price target on Alphatec (ATEC) to $14 from $25 and keeps a Buy rating on the shares. The company’s Q1 results missed consensus revenue while the management lowered its sales guidance given EOS weakness and unfavorable surgical case mix impacting revenue per case, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC: